Ing. Miloš Zeman
Twitter
AKTIVNÍ
Obsah příspěvku
According to a non-randomized phase 2 trial, an emerging therapy, which genetically modifies patient T-cells into aggressive cancer killers, showed promise in patients with relapsed B-cell lymphoma who are not good candidates for stem cell transplants. https://t.co/OcOCOji6K8 https://t.co/cSfz06qdZt
Screenshot
Screenshot není k dispozici
Metadata
| Platforma | Twitter (social) |
| Publikováno | 29.08.2022 17:38 |
| První viděn | 15.04.2026 19:22 |
| Poslední kontrola | 16.04.2026 12:57 |
| Počet slov | 0 |
| Hlídač ID | 3cc1eec1453e94ecc8ecdd0ebd5b8e2a |
| Original ID | 1564306395012517889 |
| Zdrojová URL | https://twitter.com/MZemanOficialni/status/1564306395012517889 |